Isolator glove management evaluation of regulatory guidance and framework of recommendations

31 January 2020
Fill Finish
Isolator glove management evaluation of regulatory guidance and framework of recommendations
1.23 MB

How does your organization perform glove management? Are you following best practices and using standard industry terminology? Can you benchmark your procedures within your company or with your peers? Are you able to demonstrate a harmonized approach that gives confidence to regulatory inspectors?

As many biopharmaceutical companies struggled to know how to answer these questions, they organized themselves in BioPhorum to develop the answers and write Isolator glove management: evaluation of regulatory guidance and framework of recommendations, which is a guide on best practices for the management of gloves in aseptic isolators used for filling biopharmaceutical products.

The guide has been written by a team of experts involved with creating, maintaining, justifying and operating glove programs. It evaluates regulatory and industry views on the maintenance, integrity testing and risk mitigation requirements for isolator gloves—all with the aim of building recommendations for industry best practices.

Industry need

The need for guidance was highlighted in a 2018 survey of BioPhorum members, which found that organizations had significant differences in their approach to glove management that were heightened by a lack of guidance on the best practices they should adopt.

The specific weaknesses identified in the survey included:

  • Some organizations had received regulatory challenges about the ways they described different parts of a glove
  • Different procedures exist, including the frequency and methods of testing gloves, determining when gloves should be replaced and assessing the risk on product quality of defects found in gloves
  • Organizations have different nomenclature for the various parts of gloves, making comparisons of performance difficult.

It is worth noting that the proposed Annex 1 recommends conducting mechanical testing of gloves for every batch.

The benefits

The review found that, as a minimum, these actions should be considered:

  • The upfront design of the overall isolator system
  • A well defined maintenance program that includes a risk-based, pre-emptive glove replacement procedure
  • A justified and defined glove inspection/testing procedure
  • A risk mitigation process.

The guide can be used by organizations to help them develop a program to manage the gloves they use in isolators. And those who are using isolators for the first time now have a starting point on which to base their new procedures. The guide will help minimize the likelihood of holes in gloves that may adversely affect production and so require time-consuming investigations.

“Having a best practice guide, developed by leading pharmaceutical companies and that complies with the various regulatory authorities, will help us further develop a more robust Glove Management Program within our company,” said Ed Roman, Deputy Director Filling Operators at Sanofi Pasteur.

Using the guide will help organizations:

  • Understand glove-related risks and thus facilitate deviation investigations — a harmonized glove defect approach allows for more confidence in presenting deviation investigations to inspectors
  • Understand the rationale for supplier recommendations about glove lifecycle management
  • Reduce the need for them to develop glove lifecycle management strategies on their own
  • Standardize the language for collecting data across multiple companies and so support benchmarking and improvement activities.

The team has also collaborated with a leading manufacturer that is preparing a complementary guide on the management of pinholes in gloves. This will be published in 2020 and the BioPhorum guide will be updated to ensure its content is cross-referenced to this complimentary guide.

For more information about the glove management guide, contact

A view from industry on the implication of the new Annex 1 requirements on visual inspection process
Maine and Minnesota – the BioPhorum responses to US state PFAS consultations
BioPhorum Supply Partner has become Supply Resilience
BioPhorum’s sustainability ambition – let’s move out of the holding pattern
Building a resilient business means adopting water stewardship

Advanced Therapy Medicinal Products

Advanced Therapy Medicinal Products support the quest for better and faster development of cell, gene and RNA therapies​ through connecting therapy developers, contract manufacturing, and testing organizations to gain an understanding and respond to the challenges faced by the advanced therapeutics industry.

Development Group

Development Group accelerates and improves the development process of biopharmaceutical medicines for the benefit of the patient. Replacing isolation with collaboration by providing a “safe” space where subject matter experts can work on sharing solutions and best practice on emerging industry trends, implementation of new technologies and common issues whilst ensuring their intellectual property and confidentiality is protected.

Drug Substance

Drug Substance advances excellence in drug substance manufacturing and testing, acting as an industry voice to accelerate technology adoption, implement post-approval change more rapidly and increase confidence in maintaining compliance.

Fill Finish

Fill Finish accelerates development and acceptance of sustainable world-class filling and packaging operations for drug product which meets the future needs of patients. Through innovative solutions resulting from the sharing of expertise, we can overcome common performance challenges and deliver on quality and regulatory compliance.

Information Technology

Information Technology accelerates digital maturity across the ​global pharmaceutical manufacturing industry.


BioPhorum Quality provides a dedicated, safe space for quality professionals from biomanufacturers and contract organizations to coalesce and enhance effective collaboration to address shared industry challenges.


Regulatory CMC brings leaders together who have a common goal – to improve access to medicines through innovation in the Regulatory ecosystem. It provides a dedicated space for strategic leadership and a coordinated industry voice, to move from divergence to convergence.

Supply Chain to Patient

Supply Chain to Patient transforms the performance of global pharmaceutical clinical and commercial outbound supply chains through industry collaboration by creating transparent patient-centric, resilient and agile E2E supply chains, that consistently deliver high-quality medicines ensuring an uninterrupted supply to patients.

Supply Resilience

Supply Resilience is a trusted advisory group and collaboration that is the engine for driving change across the global industry for all things relevant to the inbound supply chain. Addressing the challenges of complexity, resilience, cost, sustainability, and innovation.


Sustainability enables the industry’s transition to a low carbon, circular future – supporting members to improve patient health while respecting the planet. We activate multi-disciplinary teams drawn from our network to deliver environmental sustainability improvements across the value chain.

Technology Strategy

Technology Strategy acts as one voice of the industry to define strategy, accelerate technology transformation and support technology translation and adoption. With a purpose of enabling the future state of flexible, resilient, sustainable end-to-end biomanufacturing.

An industry perspective on understanding AAV capsid content variants
Needle On Yellow Background
An intercompany perspective on practical experiences of predicting, optimizing and analyzing high concentration biologic therapeutic formulations
The Drug Substance 2.0 Strategic Value Framework
Coloured dots on teal, next to vial
BioPhorum’s holistic approach to container closure integrity
Magnifying glass over a tablet all coloured blue
Digital Plant Maturity Model 3.0
Inaugural BioPhorum Quality face to face – get involved
The next step in building regulatory as a capability to enable strategic innovation across the BioPhorum community
A launchpad for an improved CGT outbound supply chain
DNA and Earth on blue background
A vision for the biopharmaceutical industry’s inbound supply chain
Building a resilient business means adopting water stewardship
Technology Roadmap V 2.0
BioPhorum Technology Roadmapping roadmap vision 2.0


Documents including best practices, vision statements and peer reviewed papers to help you take value back to your business.


Discussing all aspects of the biopharmaceutical industry, from digitization and knowledge management to raw materials, supply chain, sustainability and more. Learn from the perspectives of those at the forefront of the industry.


BioPhorum Connect is our podcast series that keeps you up to date with the latest news and trends in the biopharmaceutical industry. From experienced professionals to thought leaders, these podcasts bring you the insights and perspectives of experts from around the world.


A variety of resources including design tools and user requirement specifications to help you improve and streamline your business processes.

Benchmarks and Surveys

Research conducted among the BioPhorum membership providing evidence to support change and identify best practice.

Browse all

Access a variety of free tools and papers and other resources designed to provide you with up-to-date information and insights to help you make informed decisions and maximize your success. Access our resources today and start making improving and streamlining your business processes.

Bioreactivity testing in single-use system biomanufacturing
Bioreactivity testing in single-use system biomanufacturing
Bioreactivity testing in single-use system biomanufacturing
Magnifying glass over a tablet all coloured blue
Digital Plant Maturity Model 3.0
Bioreactivity testing in single-use system biomanufacturing